kidney cancer

Bristol Myers, Exelixis snag Opdivo-Cabometyx kidney cancer nod to challenge Merck, Pfizer
Fierce Pharma
Mon, 01/25/21 - 11:09 am
Bristol-Myers Squibb
Exelixis
Opdivo
Cabometyx
kidney cancer
FDA
FDA kicks off review of second kidney cancer combo based on BMS’ Opdivo
Pharmaforum
Tue, 10/20/20 - 10:33 am
Bristol-Myers Squibb
Opdivo
kidney cancer
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Tue, 08/25/20 - 11:19 am
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Endpoints
Mon, 04/20/20 - 11:59 pm
Bristol-Myers Squibb
Opdivo
Exelixis
Cabometyx
renal cell carcinoma
kidney cancer
clinical trials
2 Biotechs Battling Against Kidney Cancer
Motley Fool
Sun, 04/19/20 - 11:06 pm
kidney cancer
Nektar
Exelixis
Renal Cell Carcinoma Space in Focus: Some Key Developments
Yahoo/Zacks.com
Sat, 09/14/19 - 11:18 am
renal cell carcinoma
kidney cancer
Exelixis
Roche
Merck
Aveo Oncology
Keytruda combo cleared as first-line kidney cancer treatment in EU
Pharmaforum
Thu, 09/5/19 - 08:20 pm
Merck
Keytruda
kidney cancer
Europe
Immunicum's dendritic cell therapy flunks co-primary endpoint in 'positive' PhII
Endpoints
Thu, 08/29/19 - 10:31 am
Immunicum
immune priming
metastatic kidney cancer
kidney cancer
clinical trials
Exelixis Hits Blockbuster Status
Motley Fool
Mon, 08/5/19 - 10:45 am
Exelixis
cabozantinib
Cabometx
kidney cancer
liver cancer
Cometriq
thyroid cancer
Merck puts $1B more into oncology, with kidney cancer a focus
Biopharma Dive
Wed, 05/22/19 - 09:52 am
Merck
kidney cancer
M&A
Peloton Therapeutics
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
Xconomy
Mon, 04/22/19 - 11:11 am
Merck
FDA
Keytruda
kidney cancer
advanced renal cell carcinoma
Inlyta
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Motley Fool
Tue, 02/19/19 - 12:20 pm
Pfizer
Inlyta
kidney cancer
Merck
Keytruda
Merck, Pfizer drug combo extends kidney cancer survival -study
Yahoo/Reuters
Sun, 02/17/19 - 11:57 pm
Merck
Pfizer
kidney cancer
Keytruda
Inlyta
Sutent
Exelixis Proves Being Second Can Work Out Well
Motley Fool
Wed, 02/13/19 - 05:04 pm
Exelixis
Bristol-Myers Squibb
Cabometyx
kidney cancer
Aveo stock plunges after delay in FDA approval submission for cancer drug
Bizjournals
Fri, 02/1/19 - 12:16 am
Aveo Oncology
kidney cancer
FDA
tivozanib
advanced renal cell carcinoma
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Fierce Pharma
Tue, 11/20/18 - 12:15 pm
Roche
Merck
Pfizer
Tecentriq
kidney cancer
Exelixis Grabs Its Share of the Kidney-Cancer Treatment Market
Motley Fool
Tue, 11/6/18 - 09:34 am
Exelixis
earnings
kidney cancer
Cabometyx
Pfizer preps for BMS showdown with Bavencio kidney cancer combo data
Fierce Pharma
Sun, 10/21/18 - 11:28 pm
Pfizer
Bristol-Myers Squibb
kidney cancer
Bavencio
Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
Fierce Pharma
Thu, 10/18/18 - 01:07 pm
Merck
Keytruda
kidney cancer
Pfizer
Inlyta
Sutent
Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer
Yahoo/Reuters
Tue, 09/11/18 - 09:28 am
Merck KGaA
Bavencio
Pfizer
kidney cancer
Inlyta

Pages